EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events.

Trial Profile

EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Cinacalcet (Primary)
  • Indications Cardiovascular disorders; Heart failure; Secondary hyperparathyroidism
  • Focus Registrational; Therapeutic Use
  • Acronyms EVOLVE
  • Sponsors Amgen
  • Most Recent Events

    • 11 Jun 2015 Results of post hoc analysis have been published in the Circulation.
    • 04 Jun 2015 Results published in the Journal of Human Hypertension.
    • 01 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top